A Phase 1b/2a, Double-Blind, Placebo-Controlled, Three Arm, Randomized Study Evaluating Continuous Infusion of LSTA1 Over 4 Hours When Added to Standard of Care (SoC) Versus a Single Intravenous (IV)

Activity Type
Clinical Trial
Date
Dollar Amount
*
Grant Type
Contract
Principal Investigator
Rachna Shroff
Sponsor
Lisata Therapeutics
Unit
Cancer Center Division